Teleflex Incorporated Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
20.2%projected annual EPS growth
Analyst Coverage
11analysts covering
FY Revenue (est.)
$2.3Bnext fiscal year
FY EPS (est.)
$7.08next fiscal year
Monitoring Framework
Key Performance Indicators
Pro Forma Adjusted Constant Currency Revenue Growth Quarterly510.0%Target: 4.5% - 5.5%
Adjusted Diluted Earnings Per Share (EPS) Quarterly1.4Target: $6.25 - $6.55
Adjusted Gross Margin Quarterly6,140.0%Target: Stabilization above 60% post-divestiture
Adjusted Operating Margin Quarterly1,810.0%Target: ~23% steady-state target
Watch Items
- Completion of Strategic DivestituresTrigger: Closing of Acute Care, Interventional Urology, and OEM salesAction: Monitor regulatory approvals and transition service agreements (TSAs) in H2 2026.
- Execution of Capital Allocation PlanTrigger: Initiation of $1 billion share buyback and $800 million debt paydownAction: Track the deployment of divestiture proceeds to reduce share count and interest expense.
- Integration of BIOTRONIK Vascular Intervention BusinessTrigger: Synergy capture and margin dilution mitigationAction: Evaluate R&D productivity and sales force execution under new CEO Jason Weidman.
Research as of 19 Jun 2026